BAP5191: First in human trials

• Unité de recherche: INNOSUISSE
• Numéro de projet: 47928.1 IP-LS
• Titre du projet anglais: BAP5191: First in human trials

Description succincte (Allemand)

BAP5191: First in human trials

Description succincte (Anglais)

BAP5191: First in human trials

Résumé des résultats (Abstract) (Allemand)

BAP5191 developed by Bacoba AG will potentially become the next frontline treatment of cutaneous leishmaniasis and benefit millions. We apply for funds to access expertise and infrastructure to plan and conduct a phase I clinical trial.